← Back to Search

Progestin

Progesterone for Postpartum Smoking Relapse

Phase 4

Recruiting

Led By Sharon Allen, MD, PhD

Research Sponsored by University of Minnesota

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

history of ≥ 5 cigarettes a day for at least 6 out of the last 12 months

Be between 18 and 65 years old

Must not have

contraindications to DMPA treatment (e.g., current use of aminoglutethimide or planning to become pregnant in the next year)

contraindication to progesterone treatment (e.g., current use of drugs that may inhibit CYP3A4; current or history of deep vein thrombosis, pulmonary embolus, clotting or bleeding disorder, hypertension, stroke, heart disease, or liver dysfunction or disease; or peanut allergy)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Summary

This trial will test whether a progesterone-based contraceptive can help prevent postpartum smoking relapse and improve infant health.

Who is the study for?

This trial is for women in stable health who are 30-35 weeks pregnant, have quit smoking for at least 4 weeks, and are motivated to stay smoke-free postpartum. They must not be planning pregnancy soon after delivery, using illicit drugs or alcohol excessively, or have certain medical conditions like heart disease or a history of blood clots.

What is being tested?

The study tests if Progesterone (a hormone capsule) can help new moms avoid starting smoking again after giving birth compared to a placebo (a dummy pill). It also looks at how this might benefit the baby's health and explores if there are differences in outcomes based on race and ethnicity.

What are the potential side effects?

Progesterone may cause side effects such as headaches, breast tenderness, bloating, mood swings, allergic reactions in those with peanut allergies since the medication contains peanut oil. The placebo is unlikely to cause any direct side effects.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have smoked at least 5 cigarettes daily for 6 months in the past year.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I am not using aminoglutethimide or planning to get pregnant soon.

Select...

I cannot take progesterone due to a health condition or medication I am on.

Select...

I am currently using tobacco products or nicotine replacement therapy.

Select...

I have been diagnosed with major depression.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

2Treatment groups

Active Control

Group I: Group 2Active Control1 Intervention

Participants in this group will not receive progesterone

Group II: Group 1Active Control1 Intervention

Participants in this group will receive progesterone

0 / 5Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of MinnesotaLead Sponsor

1,413 Previous Clinical Trials

1,561,124 Total Patients Enrolled

11 Trials studying Smoking

28,069 Patients Enrolled for Smoking

University of ArizonaOTHER

525 Previous Clinical Trials

154,969 Total Patients Enrolled

1 Trials studying Smoking

1,200 Patients Enrolled for Smoking

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH

2,014 Previous Clinical Trials

2,696,555 Total Patients Enrolled

3 Trials studying Smoking

1,508 Patients Enrolled for Smoking

Media Library

Depot-Medroxyprogestereone Acetate (Progestin) Clinical Trial Eligibility Overview. Trial Name: NCT04783857 — Phase 4

Smoking Research Study Groups: Group 2, Group 1

Smoking Clinical Trial 2023: Depot-Medroxyprogestereone Acetate Highlights & Side Effects. Trial Name: NCT04783857 — Phase 4

Depot-Medroxyprogestereone Acetate (Progestin) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04783857 — Phase 4

~60 spots leftby Jun 2025

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.